• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

81 例患者的 N-of-1 前瞻性试验分析:慢性便秘或便秘型肠易激综合征的医学治疗患者不满意。

Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients.

机构信息

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

出版信息

Aliment Pharmacol Ther. 2020 Mar;51(6):629-636. doi: 10.1111/apt.15657. Epub 2020 Feb 12.

DOI:10.1111/apt.15657
PMID:32048753
Abstract

BACKGROUND

Patients with chronic constipation (CC) or with irritable bowel syndrome with constipation are often dissatisfied about their medical therapy, but their condition remains poorly defined.

AIM

To evaluate the patients' satisfaction rates and which factors predict favourable outcomes through the aggregate analysis of N-of-1 trials.

METHODS

Eighty-one outpatients with CC or with irritable bowel syndrome with constipation underwent N-of-1 trials with at least a one-month cycle of effective treatment. Three primary endpoints (satisfaction with therapy, improvement after treatment and an extended satisfaction criterion including both endpoints) were adopted to define satisfaction with therapy. Dyssynergia, resting anal pressure, colonic transit time and somatisation were assessed. The Patient Assessment of Constipation-Symptoms (PAC-SYM) questionnaire and its Modified version (M-PAC-SYM) measured constipation severity. Straining at defecation, stool frequency and form were daily recorded. K statistics for agreement and logistic regression were used at statistical analysis.

RESULTS

Satisfaction with therapy was not achieved by 43% of patients, who had a significantly lower Body Mass Index (BMI) and more severe constipation at baseline. Only the change in constipation severity according to M-PAC-SYM remained significantly associated with satisfaction with therapy (OR = 4.3; P < 0.001) at multivariate analysis.

CONCLUSIONS

Satisfaction with therapy is often an unmet need for patients with CC or with irritable bowel syndrome with constipation. Lower BMI and more severe constipation are associated with worse outcome. Changes in M-PAC-SYM reflect satisfaction with therapy. ClinicalTrials.gov no. NCT02813616.

摘要

背景

患有慢性便秘(CC)或伴有便秘型肠易激综合征的患者通常对他们的治疗效果不满意,但他们的病情仍未得到明确界定。

目的

通过对 N-of-1 试验的汇总分析,评估患者的满意度和哪些因素可预测良好的结果。

方法

81 名 CC 或伴有便秘型肠易激综合征的门诊患者接受了 N-of-1 试验,其中至少有一个月的有效治疗周期。采用三个主要终点(对治疗的满意度、治疗后改善情况和包括这两个终点的扩展满意度标准)来定义对治疗的满意度。评估了协同失调、静息肛门压力、结肠传输时间和躯体化。采用便秘患者评估症状(PAC-SYM)问卷及其改良版(M-PAC-SYM)来测量便秘严重程度。每天记录排便用力、粪便频率和形状。采用 Kappa 一致性检验和逻辑回归进行统计学分析。

结果

43%的患者对治疗不满意,他们的体重指数(BMI)明显较低,基线时便秘更严重。只有根据 M-PAC-SYM 评估的便秘严重程度的变化与治疗满意度仍有显著相关性(OR=4.3;P<0.001)。

结论

患有 CC 或伴有便秘型肠易激综合征的患者通常对治疗效果不满意。较低的 BMI 和更严重的便秘与更差的治疗结果相关。M-PAC-SYM 的变化反映了对治疗的满意度。临床试验.gov 编号:NCT02813616。

相似文献

1
Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of N-of-1 prospective trials in 81 patients.81 例患者的 N-of-1 前瞻性试验分析:慢性便秘或便秘型肠易激综合征的医学治疗患者不满意。
Aliment Pharmacol Ther. 2020 Mar;51(6):629-636. doi: 10.1111/apt.15657. Epub 2020 Feb 12.
2
Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.鲁比前列酮治疗慢性特发性便秘和肠易激综合征有效:随机对照试验的系统评价和荟萃分析
Mayo Clin Proc. 2016 Apr;91(4):456-68. doi: 10.1016/j.mayocp.2016.01.015.
3
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.新型促动力和促分泌剂在慢性特发性便秘和便秘型肠易激综合征治疗中的应用。
Adv Ther. 2009 May;26(5):519-30. doi: 10.1007/s12325-009-0027-4. Epub 2009 May 14.
4
Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype.与鲁比前列酮治疗肠易激综合征便秘亚型相关的治疗模式、症状减轻、生活质量及资源利用情况
Curr Med Res Opin. 2016 May;32(5):899-905. doi: 10.1185/03007995.2016.1150262. Epub 2016 Mar 11.
5
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.替加色罗用于治疗肠易激综合征和慢性便秘。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD003960. doi: 10.1002/14651858.CD003960.pub3.
6
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.便秘型肠易激综合征和慢性特发性便秘的现有及新出现的治疗方法:聚焦于促分泌剂。
Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27.
7
Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation.在以便秘为主的肠易激综合征和功能性便秘患者中,腹胀与生活质量较差、治疗满意度及治疗反应性相关。
Neurogastroenterol Motil. 2016 Apr;28(4):581-91. doi: 10.1111/nmo.12758. Epub 2016 Feb 12.
8
Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.ROSE-010(一种胰高血糖素样肽-1 类似物)对以便秘为主的肠易激综合征女性患者胃肠道运动功能的影响。
Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G120-8. doi: 10.1152/ajpgi.00076.2012. Epub 2012 Apr 19.
9
Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.利那洛肽治疗便秘型肠易激综合征和慢性便秘患者的疗效:一项荟萃分析。
Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi: 10.1016/j.cgh.2013.04.032. Epub 2013 May 2.
10
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.便秘型肠易激综合征:当前及新出现的药物治疗综述
World J Gastroenterol. 2014 Jul 21;20(27):8898-909. doi: 10.3748/wjg.v20.i27.8898.

引用本文的文献

1
Sennosides vs magnesium hydroxide vs polyethylene glycol as a treatment for constipation in anorectal malformation: a randomized crossover trial.番泻苷与氢氧化镁及聚乙二醇治疗肛门直肠畸形便秘的疗效比较:一项随机交叉试验
Pediatr Surg Int. 2025 Aug 26;41(1):268. doi: 10.1007/s00383-025-06174-9.
2
Correlation of the intestinal flora and its metabolites with the colonic transport function in functional constipation.功能性便秘中肠道菌群及其代谢产物与结肠传输功能的相关性
Front Microbiol. 2025 May 21;16:1591697. doi: 10.3389/fmicb.2025.1591697. eCollection 2025.
3
Effectiveness of abdominal electroacupuncture therapy for poststroke constipation: a meta-analysis.
腹部电针疗法治疗脑卒中后便秘的有效性:一项Meta分析
Front Neurol. 2024 Nov 22;15:1480681. doi: 10.3389/fneur.2024.1480681. eCollection 2024.
4
The Diagnosis and Management of Chronic Constipation in Italy: Results from a Survey Conducted among Italian Gastroenterologists.意大利慢性便秘的诊断与管理:一项针对意大利胃肠病学家的调查结果
J Clin Med. 2024 Oct 10;13(20):6047. doi: 10.3390/jcm13206047.
5
Addressing GI Health Through the Bidirectional Modulation of the Gut-Brain Axis With Herbal Extracts: A Narrative Review.通过草药提取物对肠-脑轴的双向调节来解决胃肠道健康问题:一篇叙述性综述。
Cureus. 2024 Aug 12;16(8):e66698. doi: 10.7759/cureus.66698. eCollection 2024 Aug.
6
Effects of acupuncture on gut microbiota and short-chain fatty acids in patients with functional constipation: a randomized placebo-controlled trial.针刺对功能性便秘患者肠道微生物群和短链脂肪酸的影响:一项随机安慰剂对照试验。
Front Pharmacol. 2023 Sep 1;14:1223742. doi: 10.3389/fphar.2023.1223742. eCollection 2023.
7
Exploring Pharmacological Treatments for Chronic Idiopathic Constipation in Adults: A Look Back to the Future.探索成人慢性特发性便秘的药物治疗:回顾过去,展望未来。
J Clin Med. 2023 Feb 20;12(4):1702. doi: 10.3390/jcm12041702.
8
The Value of Case Reports for Graduate Medical Education.病例报告对毕业后医学教育的价值。
J Grad Med Educ. 2022 Oct;14(5):529-532. doi: 10.4300/JGME-D-21-01115.1.
9
Efficacy and MicroRNA-Gut Microbiota Regulatory Mechanisms of Acupuncture for Severe Chronic Constipation: Study Protocol for a Randomized Controlled Trial.针刺治疗重度慢性便秘的疗效及微小RNA-肠道菌群调控机制:一项随机对照试验的研究方案
Front Med (Lausanne). 2022 Jun 28;9:906403. doi: 10.3389/fmed.2022.906403. eCollection 2022.
10
Review article: exclude or expose? The paradox of conceptually opposite treatments for irritable bowel syndrome.综述文章:排除还是暴露?概念上相反的治疗方法用于肠易激综合征的悖论。
Aliment Pharmacol Ther. 2022 Aug;56(4):592-605. doi: 10.1111/apt.17111. Epub 2022 Jul 1.